Clinical indicators for recurrent cardiovascular events in acute coronary syndrome patients treated with statins under routine practice in Thailand: an observational study

BMC Cardiovascular Disorders

Arintaya Phrommintikul⁵  John Joseph Hall³  Siriluck Gunaparn⁵  Khanchai Siriwattana⁴  Surarong Chinwong¹  Jayanton Patumanond²  Dujrudee Chinwong⁶ 

[1] Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand;Center of Excellence in Applied Epidemiology, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand;Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, Faculty of Health, University of Newcastle, Callaghan, NSW, Australia;Division of Medicine, Nakornping Hospital, Chiang Mai, Thailand;Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200Thailand;Clinical Epidemiology Program, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

关键词: Revascularization;    eGFR;    Acute coronary syndrome;    Multiple recurrent cardiovascular events;    LDL-C goal;    mg/dL;     70 ;    LDL-C <;    Subsequent cardiovascular events;   

Others  :  1216155
DOI  :  10.1186/s12872-015-0052-y

 received in 2015-02-20, accepted in 2015-06-01,  发布年份 2015

【 摘 要 】

Background

Acute coronary syndrome (ACS) patients are at very high cardiovascular risk and tend to have recurrent cardiovascular events. The clinical indicators for subsequent cardiovascular events are limited and need further investigation. This study aimed to explore clinical indicators that were associated with recurrent cardiovascular events following index hospitalization.

Methods

The data of patients hospitalized with ACS at a tertiary care hospital in northern Thailand between January 2009 and December 2012 were retrospectively reviewed from medical charts and the electronic hospital database. The patients were classified into three groups based on the frequency of recurrent cardiovascular events (nonfatal ACS, nonfatal stroke, or all-cause death) they suffered: no recurrent events (0), single recurrent event (1), and multiple recurrent events (≥2). Ordinal logistic regression was performed to explore the clinical indicators for recurrent cardiovascular events.

Results

A total of 405 patients were included; 60 % were male; the average age was 64.9 ± 11.5 years; 40 % underwent coronary revascularization during admission. Overall, 359 (88.6 %) had no recurrent events, 36 (8.9 %) had a single recurrent event, and 10 (2.5 %) had multiple recurrent events. The significant clinical indicators associated with recurrent cardiovascular events were achieving an LDL-C goal of < 70 mg/dL (Adjusted OR = 0.43; 95 % CI = 0.27–0.69, p-value < 0.001), undergoing revascularization during admission (Adjusted OR = 0.44; 95 % CI = 0.24–0.81, p-value = 0.009), being male (Adjusted OR = 1.85; 95 % CI = 1.29–2.66, p-value = 0.001), and decrease estimated glomerular filtration rate (Adjusted OR = 2.46; 95 % CI = 2.21–2.75, p-value < 0.001).

Conclusion

The routine clinical practice indicators assessed in ACS patients that were associated with recurrent cardiovascular events were that achieving the LDL-C goal and revascularization are protective factors, while being male and having decreased estimated glomerular filtration rate are risk factors for recurrent cardiovascular events. These clinical indicators should be used for routinely monitoring patients to prevent recurrent cardiovascular events in ACS patients.

【 授权许可】

   
2015 Chinwong et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al.: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32(23):2999-3054.
• [2]Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, et al.: Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003, 163(19):2345-2353.
• [3]Srimahachota S, Kanjanavanit R, Boonyaratavej S, Boonsom W, Veerakul G, Tresukosol D: Demographic, management practices and in-hospital outcomes of Thai Acute Coronary Syndrome Registry (TACSR): the difference from the Western world. J Med Assoc Thai 2007, 90(Suppl 1):1-11.
• [4]Srimahachota S, Boonyaratavej S, Kanjanavanit R, Sritara P, Krittayaphong R, Kunjara-Na-ayudhya R, Tatsanavivat P: Thai Registry in Acute Coronary Syndrome (TRACS)–an extension of Thai Acute Coronary Syndrome registry (TACS) group: lower in-hospital but still high mortality at one-year. J Med Assoc Thai 2012, 95(4):508-518.
• [5]Pocock S, Bueno H, Licour M, Medina J, Zhang L, Annemans L, Danchin N, Huo Y, Van de Werf F. Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome patients) study. Eur Heart J Acute Cardiovasc Care. 2014.Epub ahead of print.
• [6]Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E: Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008, 29(20):2473-2479.
• [7]Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E: Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol 2009, 54(25):2358-2362.
• [8]Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350(15):1495-1504.
• [9]de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292(11):1307-1316.
• [10]Kaplan RC, Heckbert SR, Furberg CD, Psaty BM: Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 2002, 55(7):654-664.
• [11]Maharaj Nakorn Chiang Mai Hospital [http://www.med.cmu.ac.th/2013/academic-departments-2/maharaj-nakorn-chiang-mai-hospital.html] Accessed 10 Feb 2015.
• [12]Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al.: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150(9):604-612.
• [13]Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, et al.: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32(14):1769-1818.
• [14]Armstrong BG, Sloan M: Ordinal regression models for epidemiologic data. Am J Epidemiol 1989, 129(1):191-204.
• [15]Ananth CV, Kleinbaum DG: Regression models for ordinal responses: a review of methods and applications. Int J Epidemiol 1997, 26(6):1323-1333.
• [16]LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H: Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol 2007, 100(5):747-752.
• [17]Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E: Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: A PROVE IT-TIMI 22 Substudy. J Am Coll Cardiol 2005, 46(8):1411-1416.
• [18]Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott SD, McCabe CH, Braunwald E, Gibson CM: Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J 2006, 27(19):2310-2316.
• [19]Chinwong D, Patumanond J, Chinwong S, Siriwattana K, Gunaparn S, Hall JJ, Phrommintikul A. Low-density lipoprotein cholesterol of less than 70 mg/dL is associated with fewer cardiovascular events in acute coronary syndrome patients: a real life cohort in Thailand. Ther Clin Risk Manag. Ther Clin Risk Manag. 2015; 11:659-67.
• [20]Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, et al.: Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008, 156(5):826-832.
• [21]Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, Reist C, McCagg A, Braunwald E, Califf RM: Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J 2014, 168(2):205-212.
• [22]O’Riordan, M. IMPROVE-IT: ‘Modest’ Benefit When Adding Ezetimibe to Statins in Post-ACS Patients [Available from: http://www.medscape.com/viewarticle/835030] Accessed 19 Nov 2014
• [23]Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, et al.: National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - executive summary. J Clin Lipidol 2014, 8(5):473-488.
• [24]Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, et al.: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63(25 Pt B):2889-2934.
• [25]National Institute for Health and Care Excellence: Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. National Clinical Guideline Centre, London; 2014.
• [26]Held C, Tornvall P, Stenestrand U: Effects of revascularization within 14 days of hospital admission due to acute coronary syndrome on 1-year mortality in patients with previous coronary artery bypass graft surgery. Eur Heart J 2007, 28(3):316-325.
• [27]Yan AT, Yan RT, Tan M, Eagle KA, Granger CB, Dabbous OH, Fitchett D, Grima E, Langer A, Goodman SG: In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score. Am J Cardiol 2005, 96(7):913-916.
• [28]Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001, 344(25):1879-1887.
• [29]Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999, 354(9180):708–715.
• [30]Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, Wheatley DJ, Pocock SJ: Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002, 360(9335):743-751.
• [31]Vanasse A, Courteau J, Niyonsenga T: Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients’ survival when delivered as usual care. BMC Cardiovasc Disord 2006, 6:21. BioMed Central Full Text
• [32]Bandara R, Medagama A, Munasinghe R, Dinamithra N, Subasinghe A, Herath J, Ratnayake M, Imbulpitiya B, Sulaiman A: Management and outcomes of acute ST-segment-elevation myocardial infarction at a tertiary-care hospital in Sri Lanka: an observational study. BMC Cardiovasc Disord 2015, 15(1):1.
• [33]D’Ascenzo F, Gonella A, Quadri G, Longo G, Biondi-Zoccai G, Moretti C, Omede P, Sciuto F, Gaita F, Sheiban I: Comparison of mortality rates in women versus men presenting with ST-segment elevation myocardial infarction. Am J Cardiol 2011, 107(5):651-654.
• [34]Wilson PW, D’Agostino R Sr, Bhatt DL, Eagle K, Pencina MJ, Smith SC, Alberts MJ, Dallongeville J, Goto S, Hirsch AT, et al.: An international model to predict recurrent cardiovascular disease. Am J Med 2012, 125(7):695-703.
• [35]Movahed MR, Hashemzadeh M, Jamal MM, Ramaraj R: Decreasing in-hospital mortality of patients undergoing percutaneous coronary intervention with persistent higher mortality rates in women and minorities in the United States. J Invasive Cardiol 2010, 22(2):58-60.
• [36]Singh M, Rihal CS, Gersh BJ, Roger VL, Bell MR, Lennon RJ, Lerman A, Holmes DR Jr: Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience. J Am Coll Cardiol 2008, 51(24):2313-2320.
• [37]Srichaiveth B, Ruengsakulrach P, Visudharom K, Sanguanwong S, Tangsubutr W, Insamian P: Impact of gender on treatment and clinical outcomes in acute ST elevation myocardial infarction patients in Thailand. J Med Assoc Thai 2007, 90(Suppl 1):65-73.
• [38]Walsh CR, O’Donnell CJ, Camargo CA Jr, Giugliano RP, Lloyd-Jones DM: Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. Am Heart J 2002, 144(6):1003-1011.
• [39]Facila L, Nunez J, Bodi V, Sanchis J, Bertomeu-Gonzalez V, Consuegra L, Pellicer M, Ferrero A, Sanjuan R, Llacer A: Prognostic value of serum creatinine in non-ST-elevation acute coronary syndrome. Rev Esp Cardiol 2006, 59(3):209-216.
• [40]Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD: Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 2006, 17(10):2886-2891.
• [41]Krumholz HM, Chen J, Chen YT, Wang Y, Radford MJ: Predicting one-year mortality among elderly survivors of hospitalization for an acute myocardial infarction: results from the Cooperative Cardiovascular Project. J Am Coll Cardiol 2001, 38(2):453-459.
• [42]Sooklim K, Srimahachota S, Boonyaratavej S, Kanjanavanit R, Siriviwattanakul N, Piamsomboon C, Ratanaprakarn R: Renal dysfunction as an independent predictor of total mortality after acute coronary syndrome: the Thai ACS Registry. J Med Assoc Thai 2007, 90(Suppl 1):32-40.
• [43]Kang YU, Jeong MH, Kim SW: Impact of renal dysfunction on clinical outcomes of acute coronary syndrome. Yonsei Med J 2009, 50(4):537-545.
• [44]Mielniczuk LM, Pfeffer MA, Lewis EF, Blazing MA, de Lemos JA, Shui A, Mohanavelu S, Califf RM, Braunwald E: Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. Am Heart J 2008, 155(4):725-731.
• [45]Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, et al.: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004, 351(13):1285-1295.
• [46]Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, Granger CB, Ohman EM, Holmes DR Jr: Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002, 106(8):974-980.
• [47]Wattanakit K, Folsom AR, Chambless LE, Nieto FJ: Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2005, 149(4):606-612.
• [48]Brugger-Andersen T, Ponitz V, Staines H, Pritchard D, Grundt H, Nilsen DW: B-type natriuretic peptide is a long-term predictor of all-cause mortality, whereas high-sensitive C-reactive protein predicts recurrent short-term troponin T positive cardiac events in chest pain patients: a prognostic study. BMC Cardiovasc Disord 2008, 8:34. BioMed Central Full Text
• [49]Zamani P, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P, Kinlay S: Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc 2013, 2(1):e003103.